Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Virchows Archiv
Published in: Virchows Archiv 3/2017

01-09-2017 | Original Article

MAGEA4 expression in bone and soft tissue tumors: its utility as a target for immunotherapy and diagnostic marker combined with NY-ESO-1

Authors: Kunio Iura, Kenichi Kohashi, Takeaki Ishii, Akira Maekawa, Hirofumi Bekki, Hiroshi Otsuka, Yuichi Yamada, Hidetaka Yamamoto, Yoshihiro Matsumoto, Yukihide Iwamoto, Yoshinao Oda

Published in: Virchows Archiv | Issue 3/2017

Login to get access

Abstract

Cancer-testis (CT) antigens have promise as targets for immunotherapy, because of their restricted expression in tumor or testis tissue. MAGEA4 is both a MAGE family member and a CT antigen, and has attracted attention as a potential immunotherapeutic target. We investigated MAGEA4 expression by immunohistochemistry in bone and soft tissue tumor specimens that consisted of 35 malignant or intermediate and 24 benign histological subtypes, in order to evaluate its possible utility as an immunotherapy target and its potential use as a diagnostic marker when combined with another CT antigen, NY-ESO-1. Among these tumors, MAGEA4 was detected in 82.2% of synovial sarcomas, 67.7% of myxoid liposarcomas, 43.8% of osteosarcomas, 41.4% of angiosarcomas, 24.6% of malignant peripheral nerve sheath tumors (MPNSTs), and 21.4% of chondrosarcomas. NY-ESO-1 expression was found in 88.2% of myxoid liposarcomas, 61.1% of synovial sarcomas, 31.3% of osteosarcomas, 21.4% of pleomorphic liposarcomas, 16.7% of desmoplastic small round cell tumors, and 14.3% of chondrosarcomas. Benign tumors and non-tumorous tissue, except for testis tissue, did not express MAGEA4 or NY-ESO-1. Combined use of MAGEA4 and NY-ESO-1 increased the sensitivity, specificity, positive predictive values, and negative predictive values for distinguishing synovial sarcoma from spindle cell tumors and other mimicking tumors, compared to individual use of MAGEA4 or NY-ESO-1. Our results support the immunotherapy targeting MAGEA4 or NY-ESO-1 can be an ancillary therapy in the above-mentioned tumors, and the potential utility of MAGEA4 as an ancillary diagnostic marker for synovial sarcoma combined with NY-ESO-1.
Appendix
Available only for authorised users
Literature
1.
Juretic A, Spagnoli GC, Schultz-Thater E, Sarcevic B (2003) Cancer/testis tumour-associated antigens: immunohistochemical detection with monoclonal antibodies. Lancet Oncol 4:104–109CrossRefPubMed
2.
Ikeda H, Lethé B, Lehmann F, van Baren JF, Baurain JF, de Smet C et al (1997) Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6:199–208CrossRefPubMed
3.
Duffour MT, Chaux P, Lurquin C, Cornelis GBT (1999) A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes. Eur J Immunol 29:3329–3337CrossRefPubMed
4.
Shafer J, Cruz C, Leen A, Ku S, Lu A, Rousseau A et al (2011) Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma. Leuk Lymphoma 51:870–880CrossRef
5.
Takahashi N, Ohkuri T, Homma S, Ohtake J, Wakita D, Togashi Y et al (2012) First clinical trial of cancer vaccine therapy with artificially synthesized helper/ killer-hybrid epitope long peptide of MAGE-A4 cancer antigen. Cancer Sci 103:150–153CrossRefPubMed
6.
Saito T, Wada H, Yamasaki M, Miyata H, Nishikawa H, Sato E et al (2014) High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine. Vaccine 32:5901–5907CrossRefPubMed
7.
Kageyama S, Ikeda H, Miyahara Y, Imai N, Ishihara M, Saito K et al (2015) Adoptive transfer of MAGE-A4 T-cell receptor gene-transduced lymphocytes in patients with recurrent esophageal cancer. Clin Cancer Res 21:2268–2277CrossRefPubMed
8.
Resnick MB, Sabo E, Kondratev S, Kerner H, Spagnoli GC, Yakirevich E (2002) Cancer-testis antigen expression in uterine malignancies with an emphasis on carcinosarcomas and papillary serous carcinomas. Int J Cancer 101:190–195CrossRefPubMed
9.
Kocher T, Zheng M, Bolli M, Simon R, Forster T, Schultz-Thater E et al (2002) Prognostic relevance of MAGE-A4 tumor antigen expression in transitional cell carcinoma of the urinary bladder: a tissue microarray study. Int J Cancer 100:702–705CrossRefPubMed
10.
Sarcevic B, Spagnoli GC, Terracciano L, Schultz-Thater E, Heberer M, Gamulin M et al (2003) Expression of cancer/testis tumor associated antigens in cervical squamous cell carcinoma. Oncology 64:443–449CrossRefPubMed
11.
Bandić D, Juretić A, Sarcević B, Separovic V, Kujundzic-Tiljak M, Hudolin T et al (2006) Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study. Croat Med J 47:32–41PubMedPubMedCentral
12.
Montoro JR, Mamede RC, Neder Serafini L, Saggioro FP, Figueiredo DL, Silva WA Jr et al (2012) Expression of cancer-testis antigens MAGE-A4 and MAGE-C1 in oral squamous cell carcinoma. Head Neck 34:1123–1128CrossRefPubMed
13.
Jäger BE, Chen Y, Drijfhout JW, Karbach J, Ringhoffer M, Jager D et al (1998) Simultaneous humoral and cellular immune response against cancer–testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 187:265–270CrossRefPubMedPubMedCentral
14.
Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME et al (2011) Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29:917–924CrossRefPubMedPubMedCentral
15.
16.
Velazquez EF, Jungbluth AA, Yancovitz M, Gnjatic S, Adams S, Oneill D et al (2007) Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)—correlation with prognostic factors. Cancer Immun 7:11PubMedPubMedCentral
17.
Kurashige T, Noguchi Y, Saika T, Ono T, Nagata Y, Jungbluth A et al (2001) NY-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade advances in brief NY-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade 1. Cancer Res 61:4671–4674PubMed
18.
Laban S, Atanackovic D, Luetkens T, Knecht R, Busch CJ, Freytag M et al (2014) Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancer. Int J Cancer 135:1142–1152CrossRefPubMed
19.
20.
21.
Lai J-P, Robbins PF, Raffeld M, Aung PP, Tsokos M, Rosenberg SA et al (2012) NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis. Mod Pathol 25:854–858CrossRefPubMed
22.
Endo M, de Graaff MA, Ingram DR, Lim S, Lev DC, Briaire-de Bruijn IH et al (2014) NY-ESO-1 (CTAG1B) expression in mesenchymal tumors. Mod Pathol 28:587–595CrossRefPubMed
23.
Christopher DMF, Julia AB, Pancras CW, Hogendoorn FM (2013) WHO classification of tumor of oft tissue and bone, 4th edn. Int Agency Res Cancer, Lyon, pp 33–43
24.
Cabezon T, Gromova I, Gromov P, Serizawa R, Timmermans Wielenga V, Kroman N et al (2012) Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer. Mol Cell Proteomics 12:381–394CrossRefPubMedPubMedCentral
25.
Iura K, Kohashi K, Hotokebuchi Y, Ishii T, Maekawa A, Yamada Y et al (2015) Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma. J Pathol Clin Res 1:144–159CrossRefPubMedPubMedCentral
26.
Italiano A, Cioffi A, Penel N, Levra MG, Delcambre C, Kalbacher E et al (2012) Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. Cancer 118:3330–3336CrossRefPubMed
27.
Jacobs JF, Brasseur F, Hulsbergen-van de Kaa CA, van de Rakt MW, Figdor CG, Adema GJ et al (2007) Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR. Int J Cancer 120:67–74CrossRefPubMed
28.
Zou C, Shen J, Tang Q, Yang Z, Yin J, Xie X et al (2012) Cancer-testis antigens expressed in osteosarcoma identified by gene microarray correlate with a poor patient prognosis. Cancer 118:1845–1855CrossRefPubMed
29.
30.
Lin C, Mak S, Meitner PA, Wolf JM, Bluman EM, Block JA et al (2002) Cancer/testis antigen CSAGE is concurrently expressed with MAGE in chondrosarcoma. Gene 285:269–278CrossRefPubMed
31.
Hruban RH, Shiu MH, Senie RT, Woodruff JM (1990) Malignant peripheral nerve sheath tumors of the buttock and lower extremity. Cancer 66:1253–1265CrossRefPubMed
32.
Nobeyama Y, Nakagawa H (2016) Aberrant demethylation and expression of MAGEB2 in a subset of malignant peripheral nerve sheath tumors from neurofibromatosis type 1. J Dermatol Sci 81:118–123CrossRefPubMed
33.
Dufresne A, Cassier P, Couraud L, Marec-Berard P, Meeus P, Alberti L et al (2012) Desmoplastic small round cell tumor: current management and recent findings. Sarcoma. doi:10.​1155/​2012/​714986
Metadata
Title
MAGEA4 expression in bone and soft tissue tumors: its utility as a target for immunotherapy and diagnostic marker combined with NY-ESO-1
Authors
Kunio Iura
Kenichi Kohashi
Takeaki Ishii
Akira Maekawa
Hirofumi Bekki
Hiroshi Otsuka
Yuichi Yamada
Hidetaka Yamamoto
Yoshihiro Matsumoto
Yukihide Iwamoto
Yoshinao Oda
Publication date
01-09-2017
Publisher
Springer Berlin Heidelberg
Published in
Virchows Archiv / Issue 3/2017
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-017-2206-z

Other articles of this Issue 3/2017

Virchows Archiv 3/2017 Go to the issue

Original Article

Spectrum of lesions derived from branchial arches occurring in the thyroid: from solid cell nests to tumors

Original Article

Inverse correlation between galectin-4 and TTF-1 in lung adenocarcinoma

Original Article

Intratumoral Fusobacterium nucleatum abundance correlates with macrophage infiltration and CDKN2A methylation in microsatellite-unstable colorectal carcinoma

Original Article

Comparison of Oncotype DX® Recurrence Score® with other risk assessment tools including the Nottingham Prognostic Index in the identification of patients with low-risk invasive breast cancer

Brief Report

Intravascular large B cell lymphoma diagnosed in random duodenal biopsies. A case report and a literature review

Original Article

How does it feel to be a pathology resident? Results of a survey on experiences and job satisfaction during pathology residency